• español
    • English
    • português
  • español 
    • español
    • English
    • português
  • Acceder
Ver documento 
  •   Inicio
  • Productos de Investigación - Creación
  • Repositorio Documental COVID-19
  • Documentos científicos relacionados a la COVID-19
  • Ver documento
  •   Inicio
  • Productos de Investigación - Creación
  • Repositorio Documental COVID-19
  • Documentos científicos relacionados a la COVID-19
  • Ver documento
JavaScript is disabled for your browser. Some features of this site may not work without it.
RecursosRecursos de apoyo¿Cómo publicar?

Listar

Todo ExpeditioComunidades & ColeccionesPor fecha de publicaciónAutoresTítulosMaterias
Esta colecciónPor fecha de publicaciónAutoresTítulosMaterias

Mi cuenta

AccederRegistro

Estadísticas

Ver Estadísticas de usoVer estadísticas Google Analytics

Drug repurposing and cytokine management in response to COVID-19: a re- view

Thumbnail

Citación

       
Exportar en: <XML METS>
Ver/
Ver portada (118.9Kb)
Fecha
2020
Autor
Heimfarth, Luana
Russo Serafini, Mairim
Saquete MartinsFilho, Paulo Ricardo
Siqueira Quintans, Jullyana Souza
Quintans Júnior, Lucindo José
Metadatos
Mostrar el registro completo del documento
Imagenes y Videos
Captura.PNG

Resumen
Coronavirus disease 2019 (COVID-19), the infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an aggressive disease that attacks the respiratory tract and has a higher fatality rate than seasonal influenza. The COVID‐19 pandemic is a global health crisis, and no specific therapy or drug has been formally recommended for use against SARS-CoV-2 infection. In this context, it is a rational strategy to investigate the repurposing of existing drugs to use in the treatment of COVID-19 patients. In the meantime, the medical community is trialing several therapies that target various antiviral and immunomodulating mechanisms to use against the infection. There is no doubt that antiviral and supportive treatments are important in the treatment of COVID-19 patients, but anti-inflammatory therapy also plays a pivotal role in the management COVID-19 patients due to its ability to prevent further injury and organ damage or failure. In this review, we identified drugs that could modulate cytokines levels and play a part in the management of COVID-19. Several drugs that possess an anti-inflammatory profile in others illnesses have been studied in respect of their potential utility in the treatment of the hyperinflammation induced by SAR-COV-2 infection. We highlight a number of antivirals, anti-rheumatic, antiinflammatory, antineoplastic and antiparasitic drugs that have been found to mitigate cytokine production and consequently attenuate the “cytokine storm” induced by SARS-CoV-2. Reduced hyperinflammation can attenuate multiple organ failure, and even reduce the mortality associated with severe COVID-19. In this context, despite their current unproven clinical efficacy in relation to the current pandemic, the repurposing of drugs with anti-inflammatory activity to use in the treatment of COVID-19 has become a topic of great interest.
Palabras clave
Cytokine; COVID-19; ACE-2; New drug; IL-6
URI
http://hdl.handle.net/20.500.12010/12808
Enlace al recurso
https://doi.org/10.1016/j.intimp.2020.106947
Colecciones
  • Documentos científicos relacionados a la COVID-19 [2292]
Comentarios

Respuesta Comentario Repositorio Expeditio

Gracias por tomarse el tiempo para darnos su opinión.


Carrera 4 # 22-61 Teléfono: (+57 1) 242 7030 - 018000111022 Fax: (+57 1) 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad.

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

 

Términos y condiciones | Políticas

 

 


Carrera 4 # 22-61 Teléfono: (+57 1) 242 7030 - 018000111022 Fax: (+57 1) 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad.

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

 

Términos y condiciones | Políticas